# Joshua Brody

Source: https://onco.cc/people/joshua-brody/  
OnCo record `joshua-brody` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Developed in situ vaccination, turning a single injected lymphoma tumour into a vaccine against the rest.

## Summary

Joshua Brody is Director of the Lymphoma Immunotherapy Program at The Mount Sinai Hospital and Tisch Cancer Institute. He is a haematologist-oncologist known for developing in situ vaccination, turning a single injected lymphoma tumour into a vaccine against the rest by combining Flt3L, radiation and a TLR agonist to induce systemic responses. His selected paper reports systemic clinical tumour regressions and potentiation of PD-1 blockade with in situ vaccination. He now leads bispecific antibody and CAR-T trials in diffuse large B-cell lymphoma.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Lymphoma Immunotherapy Program
- Specialisms: Lymphoma; In situ vaccination; Bispecific antibodies

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Brody%20JD%5BAuthor%5D

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- institutions: [The Mount Sinai Hospital / Tisch Cancer Institute](https://onco.cc/institutions/mount-sinai/)

---
JSON: https://onco.cc/api/v1/entities/joshua-brody.json